CL · Colgate-Palmolive

357 filings

CL SEC Filings

Colgate-Palmolive - 357 total filings

Filing record · 2016–202610-K1210-Q338-K102

Showing 1–50 of 357 filings

Colgate-Palmolive 8-K Report, Financial Results (Oct 30, 2026)

Colgate-Palmolive Company (CL) has reported its third-quarter 2026 financial results, demonstrating a solid performance with notable year-over-year growth. Net sales increased by 4.6% to $5,369 million, and organic sales grew by 3.6%, excluding the impact of foreign exchange and divestitures. The company's earnings per share (EPS) saw a 3% increase to $0.94 on a GAAP basis, and a more substantial 7% increase to $0.97 on a "Base Business" (non-GAAP) basis. This growth was supported by an improved gross profit margin, which rose 80 basis points to 60.2% on a GAAP basis and 90 basis points to 60.3% on a Base Business basis. The company also maintained strong market leadership in both toothpaste (41.4% global share YTD) and manual toothbrushes (33.1% global share YTD). Looking ahead, Colgate-Palmolive has narrowed its full-year net sales guidance to a 4% to 5% increase and raised its outlook for gross profit margin and Base Business EPS growth. Management highlighted continued growth momentum across its product categories and divisions, driven by both volume and pricing strategies, alongside significant advertising investments. The company reiterated its commitment to its 2030 strategy, emphasizing innovation and brand support, while expressing confidence in navigating current macroeconomic volatility to deliver consistent earnings per share growth and shareholder value.

Oct 30, 2026 10-Q

Colgate-Palmolive Quarterly Report for Q3 Ended Sep 30, 2026

Colgate-Palmolive Company reported solid financial results for the nine months ended September 30, 2026, with net sales increasing by 6.0% to $16,055 million compared to the same period in 2025. This growth was driven by a combination of volume increases, net selling price adjustments, and positive foreign exchange impacts. The company demonstrated resilience despite ongoing global macroeconomic and geopolitical challenges, which it continues to monitor closely. Despite increased raw and packaging material costs, Colgate-Palmolive managed to improve its gross profit margin to 60.8% for the nine-month period. The company is actively implementing its Strategic Growth and Productivity Program, which is expected to yield significant savings while also incurring charges in the near term. Diluted earnings per share for the nine months decreased slightly to $2.61 from $2.67 in the prior year, impacted by these restructuring charges, but on a non-GAAP basis, excluding these items, EPS increased by 7% to $2.94. The company also continued its commitment to shareholder returns through dividend payments and share repurchases.

Oct 30, 2026 10-Q

Colgate-Palmolive Quarterly Report for Q2 Ended Jun 30, 2026

Colgate-Palmolive Company reported solid financial results for the quarter and six months ended June 30, 2026. Net sales increased by 4.9% for the quarter and 6.6% for the first six months, driven by a combination of volume growth, price increases, and favorable foreign exchange. The company continues to focus on its core Oral, Personal, and Home Care segments, alongside its growing Pet Nutrition business, with strategic initiatives aimed at driving long-term growth and efficiency. Despite some operational challenges, including increased raw material costs and global economic uncertainties, Colgate-Palmolive demonstrated resilience. The company's Strategic Growth and Productivity Program is progressing, aiming to optimize its global supply chain and streamline operations, with significant charges already incurred. Diluted EPS saw a decrease on a GAAP basis due to these restructuring costs, but on a non-GAAP basis, EPS showed healthy growth, reflecting the underlying strength of the business.

Jul 31, 2026 8-K

Colgate-Palmolive 8-K Report, Financial Results (Jul 31, 2026)

Colgate-Palmolive reported second-quarter 2026 results that were mixed on the headline line but solid on the underlying business. Reported net sales rose 4.9% to $5,361 million, with organic sales up 2.4% and volume roughly flat-to-positive on a total-company basis. GAAP diluted EPS fell 5% to $0.86, but this was driven by $129 million of Strategic Growth and Productivity Program charges. On a Base Business (non-GAAP) basis, EPS rose 8% to $0.99, and Base Business gross margin and operating margin both expanded, with Base Business operating profit up 5%. Divisional performance was uneven. Latin America was the standout, with net sales up 13.7% (5.3% organic) and operating profit up 14%, while North America declined 3.0% in sales and its operating profit rose only 3%. Hill's Pet Nutrition grew 3.4% (2.1% organic) but organic volume fell, and Hill's operating profit rose 2%. Management also highlighted a 15% increase in advertising ($777 million in the quarter) as it continues to invest behind its 2030 strategy. Cash generation remained healthy, with six-month operating cash flow of $1,742 million and free cash flow before dividends of $1,476 million, while total debt declined to $7,857 million. Full-year 2026 guidance was largely maintained: net sales growth of 2% to 6% and organic sales growth of 1% to 4%, both unchanged. Gross profit margin guidance improved to roughly flat from a previously expected decline, and Base Business EPS growth guidance was narrowed upward to mid-single digits from low-to-mid single digits. Management cautioned that volatile market conditions are expected to persist for the balance of 2026. Investors should note that GAAP EPS growth guidance (double-digit growth) and Base Business EPS growth guidance differ materially because of restructuring charges, so the headline GAAP and non-GAAP figures should be weighed together.

Jul 31, 2026 8-K

Colgate-Palmolive 8-K Report, Shareholder Vote Results (May 13, 2026)

Colgate-Palmolive Co. (CL) filed an 8-K on May 13, 2026, detailing the results of its Annual Meeting of Stockholders held on May 8, 2026. The meeting primarily focused on routine governance matters. All incumbent directors standing for re-election were approved by a significant margin, indicating strong shareholder confidence in the current board's leadership and strategy. Furthermore, the company's choice of PricewaterhouseCoopers LLP as its independent auditor for the upcoming fiscal year was overwhelmingly ratified. Shareholders also provided a non-binding advisory approval for the company's executive compensation. Importantly, two significant shareholder proposals, one concerning the removal of Diversity, Equity, and Inclusion (DEI) from board candidate considerations and another advocating for an independent board chairman, failed to gain majority support, suggesting that the current board's approach to these matters aligns with the majority of the company's voting shareholders.

May 13, 2026 10-Q

Colgate-Palmolive Quarterly Report for Q1 Ended Mar 31, 2026

Colgate-Palmolive Company reported net sales of $5.324 billion for the three months ended March 31, 2026, an increase of 8.4% compared to the prior year's quarter. This growth was driven by a combination of volume increase, net selling price adjustments, and favorable foreign exchange rates, alongside a contribution from the Prime100 acquisition. Diluted earnings per share for the quarter were $0.80, a decrease from $0.85 in the same period last year, primarily impacted by charges related to the expanded Strategic Growth and Productivity Program. Excluding these program charges and other one-time items, adjusted earnings per share increased to $0.97. The company continues to navigate a challenging global environment characterized by geopolitical tensions and inflationary pressures. Despite these headwinds, Colgate-Palmolive is executing its 2030 strategy, focusing on organic sales growth, operational efficiencies, and effective capital allocation. The expansion of the Strategic Growth and Productivity Program, now expected to incur charges between $350-$550 million, aims to drive future growth and efficiency, with projected annualized pre-tax savings of $200-$300 million.

May 1, 2026 8-K

Colgate-Palmolive 8-K Report, Financial Results (May 1, 2026)

Colgate-Palmolive reported first quarter 2026 results with net sales up 8.4% to $5,324 million, but organic sales growth was a more modest 2.9%, with FX contributing 5.1 points. GAAP EPS fell 6% to $0.80 due to $171 million of Strategic Growth and Productivity Program (SGPP) charges, while Base Business (non-GAAP) EPS rose 7% to $0.97. Gross profit margin declined 20 basis points to 60.6% on both bases, and GAAP operating profit fell 10% to $964 million (Base Business operating profit rose 4% to $1,134 million). Cash generation was solid, with operating cash flow of $747 million and free cash flow before dividends of $609 million, up from $476 million a year earlier. The central new disclosure is an expansion of the SGPP, approved by the Board on April 30, 2026. Cumulative pretax charges are now estimated at $350 million to $550 million, up from $200 million to $300 million, and projected annual pretax savings are $200 million to $300 million once fully implemented. Roughly 80% to 90% of charges are expected to be cash, with substantially all incurred by December 31, 2028. Employee-related costs make up 70% to 80% of the charges, and Europe, Middle East & Africa (25% to 30%) and Corporate (20% to 25%) carry the largest shares. The higher charge estimate is a near-term cost for investors to weigh against the savings case and the execution risk the company flags. Full-year 2026 guidance for net sales (up 2% to 6%), organic sales (up 1% to 4%), and sales-based outlook was maintained. Management lowered its gross profit margin outlook to 'down' from 'up', and kept low-to-mid single-digit Base Business EPS growth and double-digit GAAP EPS growth. Notably, the GAAP EPS growth expectation is higher than the Base Business expectation, which is unusual and should be read carefully against the SGPP charge timing. North America was the weak spot, with sales down 1.8% and operating profit down 28% on a GAAP basis.

May 1, 2026 8-K

Colgate-Palmolive 8-K Report, Executive Changes (Apr 9, 2026)

Colgate-Palmolive Company (CL) announced a significant leadership transition within its legal department. Jennifer M. Daniels, the long-serving Chief Legal Officer and Secretary since 2014, has informed the company of her intention to retire in 2026. This departure marks the end of an era for a key executive who has guided the company's legal affairs for over a decade. In response to Ms. Daniels' upcoming retirement, the Board of Directors has elected Betsy Fishbone, currently the Executive Vice President and Deputy Chief Legal Officer, to succeed her as Chief Legal Officer and Secretary, effective June 1, 2026. To ensure a seamless handover and leverage Ms. Daniels' extensive experience, she will transition to the role of Vice Chair of the Company, also effective June 1, 2026. This move is designed to facilitate an orderly transition of responsibilities and maintain continuity in the company's legal leadership.

Apr 9, 2026 8-K

Colgate-Palmolive 8-K Report, Corporate Update (Mar 17, 2026)

Colgate-Palmolive filed an 8-K under Item 8.01 to disclose a realignment of its reportable operating segments, effective for the quarter ending March 31, 2026, as part of its previously announced Strategic Growth and Productivity Program. The Europe and Africa/Eurasia segments (excluding Russia and Belarus) and the Skin Health business, previously in North America, will combine into a new Europe, Middle East & Africa (EMEA) segment. Russia and Belarus move into Asia Pacific. The company states this is a presentation change with no effect on historical consolidated results, financial position, or cash flows, and that the recast figures are not a restatement. Exhibit 99 provides unaudited recast segment data for FY2023 through FY2025 and for the 2025 quarterly periods. On the recast basis, FY2025 net sales were $20.38 billion, up about 1.4% from $20.10 billion in FY2024. Consolidated operating profit fell about 23% to $3.31 billion from $4.27 billion, driven mainly by Corporate expense, which rose to a $1.72 billion charge from $784 million. Within the segments, EMEA was the standout, with operating profit up about 15% to $938 million, and Pet Nutrition rose about 10% to $1.06 billion. North America, Latin America, and Asia Pacific operating profit each declined roughly 8%. For investors, the key takeaways are that the new EMEA structure gives a clearer view of the Strategic Growth and Productivity Program's European effects, and that the recast data shows the 2025 profit decline sits largely in Corporate costs rather than in segment-level operations. The filing does not explain the Corporate charge, so the drivers should be confirmed in the 10-K and subsequent earnings materials. Figures in the exhibit are unaudited and should be read alongside the FY2025 Form 10-K.

Mar 17, 2026 8-K

Colgate-Palmolive 8-K Report, Executive Changes (Mar 12, 2026)

Colgate-Palmolive Company (CL) has announced a significant change in its Board of Directors. Effective March 15, 2026, Dr. Christopher S. Boerner, currently the Board Chair and CEO of Bristol-Myers Squibb, will join the Colgate-Palmolive Board. Dr. Boerner's extensive experience in global business leadership, particularly within the biopharmaceutical and healthcare sectors, is expected to bring valuable expertise to the company's strategic direction. In conjunction with this appointment, Steven A. Cahillane has informed the Board that he will not seek reelection at the upcoming Annual Meeting of Stockholders on May 8, 2026. This decision is attributed to the increased demands of his new role as CEO of The Kraft Heinz Company. These board-level transitions signal a refresh in leadership perspective and potentially a strengthened focus on areas complementary to Colgate-Palmolive's existing business.

Mar 12, 2026 10-K

Colgate-Palmolive Annual Report, Year Ended Dec 31, 2025

Colgate-Palmolive's 2025 results show modest top-line growth masked by a large non-cash impairment. Net sales rose 1.4% to $20,382 million, driven by 2.1% net price increases, partially offset by 0.4% volume declines and a 0.3% FX headwind. Organic sales grew 1.4%, with Oral, Personal and Home Care up 1.5% and Hill's Pet Nutrition up 1.2% organically. Gross margin slipped to 60.1% (down 40 bps reported) as raw and packaging material inflation of roughly 420 bps was only partly offset by funding-the-growth savings of 260 bps. GAAP operating profit fell 23% to $3,306 million because of a $919 million goodwill and intangible impairment tied to the skin health business (primarily Filorga), along with a $99 million ERISA settlement charge. Excluding these and other items, operating profit was flat at $4,347 million and diluted EPS was $3.69 non-GAAP versus $2.63 GAAP. Management expects softness in its categories seen in 2025 to continue into 2026, citing macroeconomic pressure, high interest rates, FX volatility and tariff-related trade developments. It is also pursuing a three-year Strategic Growth and Productivity Program with estimated pre-tax charges of $200 to $300 million through 2028, and it is operating under its 2030 strategy. Cash generation remained solid, with operating cash flow up 2% to $4,198 million and capex of $564 million. Shareholder returns were significant: dividends paid totaled $1,823 million (quarterly dividend raised to $0.52 from $0.50) and buybacks totaled $1,210 million. Total debt was stable at about $7.99 billion. The company's shareholders' equity fell to a near-zero $54 million after the impairment, buybacks and dividends, so investors should focus on cash flow and leverage rather than book equity. For investors, the key takeaways are that underlying profitability held up despite input-cost inflation, that 2026 growth is expected to remain soft, and that the impairment reflects weakness in the skin health portfolio, particularly in China, rather than a broader franchise problem. Walmart represents about 11% of net sales, and the Venezuela and Russia exposures are noted but are not material to the consolidated statements.

Feb 23, 2026 8-K

Colgate-Palmolive 8-K Report, Financial Results (Jan 30, 2026)

Colgate-Palmolive reported fourth quarter and full-year 2025 results on January 30, 2026, and the headline is a large non-cash write-down that obscures a steady underlying business. GAAP diluted EPS fell 25% to $2.63 for the year, and Q4 GAAP EPS was $(0.05), driven by a $794 million after-tax goodwill and intangible impairment tied to the skin health business (primarily Filorga), which management cut after weaker-than-expected performance, particularly in China. On a Base Business (non-GAAP) basis, full-year EPS rose 3% to $3.69 and Q4 EPS rose 4% to $0.95. Full-year net sales grew 1.4% to $20.4 billion, with organic sales also up 1.4%, though a 0.7% drag came from lower private label pet volume. Q4 organic growth accelerated to 2.2% and net sales rose 5.8%, helped by 3.1 points of favorable FX. Cash generation was strong, with record operating cash flow of $4.2 billion and free cash flow before dividends of $3.6 billion. The company returned $2.9 billion to shareholders through dividends ($1.8 billion) and buybacks ($1.2 billion). Base Business operating margin for the year was roughly 21.3%, down about 40 basis points, while Base Business gross margin fell about 50 basis points to 60.1%, reflecting cost and mix pressures. Management also introduced a new 2030 strategy and guided 2026 to net sales growth of 2% to 6% and organic growth of 1% to 4%, with GAAP EPS growing double digits and Base Business EPS growing low to mid single digits. Management said the operating environment will remain difficult in the near term. For investors, the key question is whether the impairment marks a one-time reset or signals weakening in the skin health franchise and China. The Base Business numbers show modest but steady earnings growth and healthy cash returns, while the GAAP figures are distorted by the charge. The guidance implies a return to GAAP EPS growth in 2026, but the gap between GAAP and Base Business outlook and the mention of a sluggish category backdrop mean investors should watch whether Q4 organic momentum can be sustained.

Jan 30, 2026 8-K

Colgate-Palmolive 8-K Report, Corporate Update (Nov 10, 2025)

Colgate-Palmolive Company (CL) has filed an 8-K report detailing a significant debt financing transaction. On November 3, 2025, the company entered into an underwriting agreement for the issuance and sale of €600,000,000 of 3.250% Senior Notes due 2035. This offering was made under the company's existing automatic shelf registration statement on Form S-3. These notes were issued on November 10, 2025, under an indenture dated November 15, 1992. The underwriting agreement includes standard provisions for representations, warranties, covenants, and indemnification from both the company and the underwriters. This filing provides transparency on the terms of the debt issuance and the associated legal documentation.

Nov 10, 2025 8-K

Colgate-Palmolive 8-K Report, Financial Results (Oct 31, 2025)

Colgate-Palmolive reported Q3 2025 results that were mixed: net sales rose 2.0% to $5,131 million, but organic sales grew only 0.4%, and the gain was held back by a 0.8-point drag from exiting low-margin private label pet sales. GAAP EPS rose 1% to $0.91, and Base Business EPS was flat at $0.91. Gross margin fell 170 basis points to 59.4% on a GAAP basis (190 basis points on a Base Business basis), and operating profit declined 1% as reported and 2% on a Base Business basis. North America (organic sales -0.5%, operating profit down 8%) and Latin America (operating profit down 8%) were the weak spots, while Europe (operating profit up 16%) and Africa/Eurasia were the bright spots. Management cut its full-year 2025 organic sales growth guidance to 1%-2%, from the low end of 2%-4%, and now includes roughly a 70 basis point drag from the private label pet exit. It maintained its EPS guidance of low-single-digit growth and now expects gross margin roughly in line with the year-to-date 60.1%, down from roughly flat previously. The filing also discloses the Strategic Growth and Productivity Program, a three-year restructuring with estimated cumulative pre-tax charges of $200-$300 million, about 75%-85% of which will be cash expenditures, to be substantially incurred by December 31, 2028. For investors, the central questions are whether the 2030 strategy and the productivity program can restore organic growth and margins, and whether the savings from the program will offset the pressure from slowing category growth, tariffs, and gross margin erosion. Balance sheet metrics are stable, with year-to-date operating cash flow of $2,745 million and free cash flow before dividends of $2,358 million, though total debt rose to $8,419 million. Note that the filing is partly a furnished press release, and the forward-looking statements it contains carry the usual risks.

Oct 31, 2025 10-Q

Colgate-Palmolive Quarterly Report for Q3 Ended Sep 30, 2025

Colgate-Palmolive Company (CL) reported a slight increase in net sales for the third quarter of 2025, reaching $5.131 billion, a 2.0% rise compared to the prior year's period. This growth was primarily driven by net selling price increases and a positive foreign exchange impact, though it was partially offset by a decline in sales volume. Diluted Earnings Per Share (EPS) saw a modest increase to $0.91 from $0.90 year-over-year. The company experienced higher raw and packaging material costs, which led to a decrease in gross profit margin. Despite this pressure, Colgate-Palmolive implemented cost-saving initiatives and pricing strategies to mitigate the impact. The company also announced a new "Strategic Growth and Productivity Program" aimed at driving future growth and efficiencies, which is expected to incur pre-tax charges between $200 and $300 million over the next three years. Management remains focused on driving organic sales growth and operational efficiencies despite challenging global macroeconomic conditions.

Oct 31, 2025 10-Q

Colgate-Palmolive Quarterly Report for Q2 Ended Jun 30, 2025

Colgate-Palmolive Company (CL) reported its financial results for the second quarter and first half of 2025. For the quarter, net sales increased by 1.0% to $5.11 billion, driven by net selling price increases, while volume remained flat. The Hill’s Pet Nutrition segment showed stronger growth at 3.8%, aided by the recent acquisition of Prime100. Diluted Earnings Per Share (EPS) saw an increase to $0.91 for the quarter. For the first six months, net sales saw a slight decrease of 1.0% to $10.02 billion, with organic sales growing 1.6% driven by price increases and a slight volume contribution from the Pet Nutrition segment. The company continues to manage through inflationary pressures and global economic uncertainties, implementing cost-saving initiatives and revenue growth management strategies.

Aug 1, 2025 8-K

Colgate-Palmolive 8-K Report, Financial Results (Aug 1, 2025)

Colgate-Palmolive reported second-quarter 2025 results that were modestly positive at the top and bottom line but showed underlying pressure. GAAP net sales rose 1.0% to $5.11 billion, and organic sales grew 1.8%, though that figure absorbed a 0.6-point drag from the planned exit of private label pet sales. GAAP diluted EPS rose 2% to $0.91, while Base Business (non-GAAP) EPS rose 1% to $0.92. Gross margin contracted 50 basis points on a GAAP basis (70 bps on a Base Business basis), and Base Business operating margin fell 80 bps to 21.3%. Growth was uneven by region: Latin America and North America were weak in organic terms and Asia Pacific was flat, while Hill's (Pet Nutrition) and Africa/Eurasia were the strongest performers. Management narrowed its full-year 2025 organic sales growth guidance to the low end of its 2% to 4% range, a signal of softer demand, while keeping its guidance for roughly flat gross margin and advertising as a percentage of sales and low-single-digit EPS growth. The company also announced a new three-year productivity program, approved July 31, 2025, tied to its 2030 strategy. It is expected to generate cumulative pre-tax charges of $200 to $300 million, with substantially all charges recognized by December 31, 2028, and recorded in the Corporate segment. Investors should weigh near-term restructuring costs against the potential margin and cost benefits from simplifying the organization and optimizing the supply chain. Free cash flow before dividends was $1.25 billion for the first half of 2025, down from $1.43 billion a year earlier, and total debt rose to $8.76 billion from $7.95 billion at year-end 2024, partly reflecting a 2025 acquisition (Prime100 pet food). Overall, the quarter shows resilient earnings and share-count-driven EPS growth against a backdrop of slowing organic growth, margin pressure, and a new cost program that management expects to weigh on reported results through 2028.

Aug 1, 2025 8-K

Colgate-Palmolive 8-K Report, Executive Changes (May 29, 2025)

Colgate-Palmolive Company (CL) announced a significant executive appointment and a planned retirement, signaling strategic shifts in its leadership. The company has appointed Shane Grant as its new Chief Operating Officer, Americas, effective June 16, 2025. Mr. Grant brings extensive international experience from leadership roles at Danone and The Coca-Cola Company, most recently serving as Group Deputy CEO and CEO Americas at Danone. In addition, Prabha Parameswaran, currently Group President, Growth and Strategy, will transition to Vice Chair effective June 16, 2025, ahead of her planned retirement on October 1, 2025. The company has also made other executive promotions, including Panagiotis Tsourapas to Chief Operating Officer, Europe, Asia Pacific, Africa Eurasia, Skin Health & Global Customer Development, and John Hazlin to Chief Growth Officer, both effective June 16, 2025. These appointments suggest a focus on strengthening regional operations and driving global growth initiatives.

May 29, 2025 8-K

Colgate-Palmolive 8-K Report, Shareholder Vote Results (May 14, 2025)

Colgate-Palmolive Company (CL) has filed an 8-K detailing the results of its Annual Meeting of Stockholders held on May 9, 2025. The meeting focused on routine corporate governance matters, including the election of directors, ratification of the independent auditor, and advisory votes on executive compensation and specific stockholder proposals. All incumbent directors proposed for re-election were overwhelmingly approved, indicating strong shareholder confidence in the current leadership and board composition. The company's choice of PricewaterhouseCoopers LLP as its auditor for the upcoming fiscal year was also ratified with substantial support.

May 14, 2025 8-K

Colgate-Palmolive 8-K Report, Corporate Update (May 2, 2025)

Colgate-Palmolive Company (CL) has announced the successful issuance and sale of $500,000,000 aggregate principal amount of its 4.200% Senior Notes due 2030. This debt offering was completed under the Company's existing automatic shelf registration statement and was formalized through an underwriting agreement with Citigroup Global Markets Inc. and Scotia Capital (USA) Inc. as representatives of the underwriters. The issuance of these notes, which matures in 2030, is a standard capital markets transaction intended to support the company's ongoing operations and strategic initiatives. Investors should note that this 8-K filing primarily concerns the details of this debt issuance, including the underwriting agreement and the terms of the notes. While it does not disclose any new financial performance metrics or strategic shifts, it signals the company's proactive approach to managing its capital structure and securing funding. The fixed coupon rate of 4.200% provides a clear cost of debt for this issuance, and the transaction is subject to customary representations, warranties, and indemnification clauses.

May 2, 2025 8-K

Colgate-Palmolive 8-K Report, Financial Results (Apr 25, 2025)

Colgate-Palmolive reported first quarter 2025 results on April 25, 2025, with a mixed picture: GAAP net sales fell 3.1% to $4.91 billion, but organic sales rose 1.4%, meaning the decline was driven almost entirely by a 4.4% foreign exchange headwind. Volume was roughly flat (-0.1%) and pricing added 1.5%. Profitability held up better than sales. GAAP diluted EPS rose 2% to $0.85, and Base Business (non-GAAP) EPS rose 6% to $0.91, helped by a gross margin expansion of 80 basis points to 60.8% and a 120 basis point increase in GAAP operating margin to 21.9%. Operating profit grew 3% on a GAAP basis. Net cash from operations was $600 million, and free cash flow before dividends was $476 million, down from $555 million a year earlier. Segment performance was uneven. Hill's (Pet Nutrition) was the standout, with operating profit up 30% and margin up 510 basis points, and Europe showed strong organic growth of 5.4% and operating profit up 12%. Latin America was the weak spot, with net sales down 8.7% (including a 12.7% FX drag) and operating profit down 14%. North America and Africa/Eurasia also saw profit declines. Management highlighted leadership in toothpaste (40.9% global share) and manual toothbrushes (31.9%). The company revised its full-year 2025 guidance. Net sales are now expected to be up low single digits, with a low-single-digit FX headwind, and organic sales growth is now 2% to 4%. Management cited tariffs and volatile global markets as ongoing risks. GAAP and Base Business EPS are both expected to grow low single digits. Note that this 8-K furnishes the earnings release under Item 2.02 and is not deemed filed under the Exchange Act.

Apr 25, 2025 10-Q

Colgate-Palmolive Quarterly Report for Q1 Ended Mar 31, 2025

Colgate-Palmolive Company reported first-quarter 2025 results with a slight decrease in net sales to $4.911 billion, down 3.1% from $5.065 billion in the prior year. This decline was primarily driven by a 4.4% negative impact from foreign exchange and a 0.1% volume decrease, partially offset by a 1.5% increase in net selling prices. On an organic basis (excluding foreign exchange, acquisitions, and divestitures), net sales grew by 1.4%. Diluted earnings per share increased to $0.85 from $0.83 in the prior year, showing a positive trend despite top-line pressure. The company experienced mixed performance across its segments, with Oral, Personal, and Home Care net sales decreasing 4.3% (though organic sales grew 1.0%), while Hill's Pet Nutrition saw a 1.5% increase in net sales (with organic sales up 2.9%). The company highlighted improvements in gross profit margin to 60.8% from 60.0%, driven by cost savings, pricing actions, and favorable mix, which helped to offset increased raw and packaging material costs. Management indicated continued focus on organic sales growth, operational efficiencies, and capital allocation, including increased dividends and a new share repurchase program.

Apr 25, 2025 10-K

Colgate-Palmolive Annual Report, Year Ended Dec 31, 2024

Colgate-Palmolive's FY2024 10-K shows a company that grew reported net sales 3.3% to $20.1 billion, with organic sales up 7.4% driven by 3.1% volume growth and 4.4% net price increases, partly offset by a 4.1% foreign exchange headwind. Gross margin expanded to 60.5% (60.6% non-GAAP) on funding-the-growth savings and pricing, while SG&A rose to 38.5% of sales as advertising spend increased 14.7% to $2.72 billion (13.5% of sales). GAAP operating profit rose 7% to $4.27 billion, and non-GAAP operating margin improved 100 bps to 21.7%. GAAP diluted EPS was $3.51 (non-GAAP $3.60, up 11%), versus $2.77 GAAP in 2023, which was depressed by the ERISA litigation charge and a foreign tax matter. Cash generation strengthened, with operating cash flow up 10% to $4.1 billion and capex falling to $561 million. The company returned about $3.5 billion to shareholders through $1.79 billion in dividends and $1.74 billion in buybacks, which pushed total equity down to $544 million and left the balance sheet heavily leveraged relative to book value. Total debt eased to about $7.9 billion. Hill's Pet Nutrition was the standout segment, with operating margin up 270 bps to 21.5%, while Latin America delivered strong organic growth of 16.8% despite severe currency headwinds. Key risks flagged for investors include ongoing geopolitical tensions (Ukraine, the Middle East, China-Taiwan), new U.S. tariffs announced in February 2025, rising advertising and input-cost pressure, retailer concentration (Walmart at roughly 11% of sales), hyperinflation in Argentina and Türkiye, and a pending ERISA judgment that may require a 2025 pension cash contribution. Management expects a challenging macro environment and volatile category growth in 2025.

Feb 13, 2025 8-K

Colgate-Palmolive 8-K Report, Financial Results (Jan 31, 2025)

Colgate-Palmolive reported fourth quarter and full year 2024 results on January 31, 2025, marking its first year with net sales above $20 billion ($20,101M, up 3.3% GAAP). Organic sales grew a strong 7.4% for the full year, the sixth consecutive year at or above the company's 3%-5% target, with growth in every division and all four categories. The gap between the 3.3% reported and 7.4% organic growth reflects a 4.1% foreign exchange headwind. Profitability improved markedly: GAAP gross margin expanded 230 basis points to 60.5%, GAAP diluted EPS rose 27% to $3.51, and Base Business (non-GAAP) EPS rose 11% to $3.60. Operating leverage and a 15% increase in advertising spending ($2,720M) were key features of the year. Fourth quarter results were softer at the top line: net sales were flat (-0.1%) and organic sales rose 4.3%, with Latin America (-7.2% reported, heavily hit by a 16.4% FX drag) and North America (-1.0% reported, -0.7% organic) the weakest areas. Volume growth of 2.5% and pricing of 1.8% drove organic growth. Hill's Pet Nutrition was the standout, with operating profit up 19% and margin expanding 340 basis points, while North America operating profit fell 11%. Quarterly GAAP EPS rose 3% to $0.90 and Base Business EPS rose 5% to $0.91. For 2025, management guided to roughly flat net sales including a mid-single-digit FX headwind, organic growth within its 3%-5% target (net of the planned exit from private label pet nutrition), gross margin expansion, flat to slightly higher advertising, and low-to-mid single-digit Base Business EPS growth (mid-single-digit on a GAAP basis). Guidance is based on current spot rates. Management also cited tariffs, geopolitical tensions, and currency as risks to the outlook. Free cash flow before dividends rose to $3.5 billion, and the company returned $3.4 billion to shareholders through dividends and buybacks.

Jan 31, 2025 8-K

Colgate-Palmolive 8-K/A Report, Financial Results (Jan 24, 2025)

Colgate-Palmolive's 8-K/A (Amendment No. 1) is a technical filing: it adds an Item 2.02 tag to the October 25, 2024 8-K so EDGAR reflects the earnings release correctly. No substantive content from the original report changed. The attached Exhibit 99.1 (Q3 2024 results) is the substantive material for investors. Q3 2024 net sales rose 2.4% to $5,033 million, organic sales rose 6.8%, and GAAP diluted EPS rose 5% to $0.90 (Base Business EPS of $0.91, up 6%). Gross margin expanded 260 basis points to 61.1%, and operating profit grew 4% to $1,065 million. Management raised full-year 2024 guidance for net sales growth (3% to 5%), organic sales growth (7% to 8%), and Base Business EPS growth (10% to 11%). Nine-month operating cash flow was $2,838 million, and free cash flow before dividends was $2,461 million. The filing also includes Item 8.01, which discloses a segment realignment effective July 1, 2024. Skin health businesses formerly reported in Europe now sit within North America. Management recast historical geographic segment data (Exhibit 99.2) to reflect the change. The company states this has no effect on consolidated results, financial position, or cash flows, and that the recast does not restate previously issued financials. Investors comparing regional performance should use the recast figures, since North America and Europe growth rates are not comparable to pre-July 2024 reporting. Europe's reported Q3 operating profit growth of 10% and North America's decline of 9% both reflect this realignment, so the regional comparison is partly a reporting artifact. The quarter's main watch items are the sharp divergence across divisions and regions and the sizable FX headwind. Hill's Pet Nutrition operating profit rose 28% with margin up 390 basis points. Latin America organic sales grew 14.2%, but reported sales fell 3.2% due to a 17.4% foreign exchange drag. Advertising spend rose 16% to $694 million in the quarter, and management expects continued strong investment through year-end.

Jan 24, 2025 8-K

Colgate-Palmolive 8-K Report, Corporate Update (Oct 25, 2024)

Colgate-Palmolive reported third-quarter 2024 results on October 25, 2024 that beat its own expectations on both top and bottom line. Net sales rose 2.4% to $5,033 million, while organic sales grew a stronger 6.8% (against an 8.8% organic gain in the prior-year quarter), with volume up 3.7% and pricing contributing 3.1%. Foreign exchange was a 4.4-point headwind. GAAP diluted EPS rose 5% to $0.90, and Base Business (non-GAAP) EPS rose 6% to $0.91. GAAP gross margin expanded 260 basis points to 61.1%, marking the sixth consecutive quarter of gross margin expansion, and advertising spending rose 16% to $694 million. Hill's Pet Nutrition was the standout division, with operating profit up 28% and margin up 390 basis points, while North America operating profit fell 9%. Management raised its full-year 2024 guidance. Net sales growth is now expected at 3% to 5% (up from 2% to 5%), including a mid-single-digit negative FX impact; organic sales growth is now 7% to 8% (up from 6% to 8%); and Base Business EPS growth is now 10% to 11% (up from 8% to 11%). Year-to-date operating cash flow was $2,838 million, and free cash flow before dividends was $2,461 million, up from $2,101 million a year earlier. Total debt declined to $8,436 million. Separately, under Item 8.01, the company realigned its skin health business, moving it from the Europe segment into North America effective July 1, 2024, following management changes. Historical geographic segment data has been recast accordingly. The company states this has no effect on consolidated results or financial position and is not a restatement. Investors comparing segment trends should use the recast figures, since North America and Europe results are not directly comparable to previously reported numbers.

Oct 25, 2024 10-Q

Colgate-Palmolive Quarterly Report for Q3 Ended Sep 30, 2024

Colgate-Palmolive Company reported solid financial results for the nine months ended September 30, 2024, with net sales increasing by 4.5% to $15.2 billion and net income attributable to the company rising 36% to $2.15 billion. Diluted EPS also saw a significant increase to $2.61 from $1.90 in the prior year period. The company demonstrated strong organic sales growth of 8.5% for the nine-month period, driven by both volume and pricing strategies across its Oral, Personal and Home Care, and Pet Nutrition segments. Gross profit margin improved to 60.6% from 57.7% in the prior year, reflecting cost savings and pricing actions, though partially offset by higher raw material costs. The company continues to navigate a challenging macroeconomic environment characterized by inflation and foreign currency volatility, particularly in hyper-inflationary economies. Despite these headwinds, Colgate-Palmolive maintained its market share in global toothpaste and manual toothbrush categories. The company's strategic focus on innovation, efficiency through its "funding-the-growth" initiatives, and investment in brands positions it for continued resilience and growth, even amidst global economic uncertainties and increased competition.

Oct 25, 2024 10-Q

Colgate-Palmolive Quarterly Report for Q2 Ended Jun 30, 2024

Colgate-Palmolive Company (CL) reported robust financial results for the second quarter and first half of 2024, demonstrating strong top-line growth driven by both volume and pricing. For the three months ended June 30, 2024, Net sales increased by 4.9% to $5,058 million, and organic sales grew by 9.0%. This growth was supported by solid performance in both the Oral, Personal and Home Care segment and the Pet Nutrition segment (Hill's Pet Nutrition). Diluted Earnings Per Share (EPS) reached $0.89, a significant increase from $0.60 in the prior year period. The company also saw an improvement in Gross profit margin to 60.6% and Operating profit margin to 21.6%, reflecting successful cost-saving initiatives and pricing strategies. The first half of 2024 also showed positive momentum with Net sales up 5.5% to $10,124 million and organic sales up 9.4%. Diluted EPS for the six months ended June 30, 2024, was $1.71, up from $1.05 in the prior year. The company continues to invest in brand building and innovation, as evidenced by increased advertising spend, positioning it for continued growth in a challenging global economic environment.

Jul 26, 2024 8-K

Colgate-Palmolive 8-K Report, Financial Results (Jul 26, 2024)

Colgate-Palmolive reported second-quarter 2024 results that beat on the top and bottom line, with net sales up 4.9% to $5,058 million and organic sales up 9.0% (on top of 8.2% a year earlier). Growth was broad-based: every operating division posted positive volume growth, with organic volume up 4.7% overall and pricing contributing 4.2%. GAAP diluted EPS rose 48% to $0.89, while Base Business (non-GAAP) EPS rose 18% to $0.91. Gross profit margin expanded 280 basis points to 60.6% on a GAAP basis (300 bps to 60.8% Base Business), marking the fourth consecutive quarter of gross margin expansion. Operating profit grew 12% on a GAAP basis to $1,092 million, and Base Business operating profit grew 13% to $1,118 million. Management continued to reinvest in the brand, with advertising spending up 18% to $706 million in the quarter. Net cash provided by operations was $1,671 million for the first six months of 2024, up from $1,457 million, and free cash flow before dividends rose to $1,428 million from $1,110 million, helped by lower capital expenditures. Total debt was $8,676 million at June 30, 2024, and net debt (debt less cash and marketable securities) was $7,341 million, slightly below year-end 2023. Share repurchases of $989 million in the first half were the largest use of cash after dividends of $867 million. The company raised its full-year 2024 organic sales growth guidance to 6% to 8% from 5% to 7%, and raised its Base Business EPS growth guidance to 8% to 11% from mid-to-high single digits. Net sales growth guidance of 2% to 5% was maintained, though it includes a mid-single-digit negative foreign exchange impact. GAAP EPS guidance still calls for double-digit growth. The primary risks flagged are currency headwinds, particularly in Latin America and Africa/Eurasia, and ongoing geopolitical uncertainty, including the war in Ukraine and the Israel-Hamas conflict.

Jul 26, 2024 8-K

Colgate-Palmolive 8-K Report, Shareholder Vote Results (May 15, 2024)

Colgate-Palmolive Company (CL) filed an 8-K report on May 14, 2024, detailing the outcomes of its Annual Meeting of Stockholders held on May 10, 2024. The report indicates strong support for the company's slate of directors, with all nominated individuals elected to the board. Additionally, shareholders overwhelmingly ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the upcoming fiscal year. The company's executive compensation plan received advisory approval from stockholders, reflecting a positive sentiment towards the remuneration structure. However, a stockholder proposal advocating for an independent Board Chairman was not approved, suggesting a preference for the current governance model among a significant portion of the voting shareholders. These results provide a clear picture of shareholder sentiment on key governance and oversight matters.

May 15, 2024 10-Q

Colgate-Palmolive Quarterly Report for Q1 Ended Mar 31, 2024

Colgate-Palmolive Company reported robust financial results for the first quarter of 2024, demonstrating strong top-line growth and improved profitability. Net sales increased by 6.2% year-over-year, driven by both volume growth and significant price increases, with organic sales growing by 9.8%. This growth was broad-based across its core Oral, Personal and Home Care segment and the Pet Nutrition segment. The company also showcased enhanced profitability, with gross profit margin expanding to 60.0% from 56.9% in the prior year, attributed to higher pricing and cost savings initiatives. Operating profit saw a substantial 15% increase, reflecting improved operational efficiencies and strategic pricing actions. Diluted Earnings Per Share (EPS) rose to $0.83, up significantly from $0.45 in the first quarter of 2023, highlighting the company's ability to translate sales growth into enhanced shareholder returns. The company also announced an increase in its quarterly common stock dividend, signaling confidence in its financial health and commitment to returning value to shareholders.

Apr 26, 2024 8-K

Colgate-Palmolive 8-K Report, Financial Results (Apr 26, 2024)

Colgate-Palmolive reported first quarter 2024 results on April 26, 2024, with broad-based strength. Net sales rose 6.2% to $5,065 million, and organic sales (a non-GAAP measure excluding foreign exchange and M&A) grew 9.8%, with growth in every division and category. Pricing contributed 8.5 points while organic volume added 1.3 points and foreign exchange subtracted 3.6 points. GAAP diluted EPS increased 84% to $0.83, while Base Business (non-GAAP) EPS rose 18% to $0.86. The year-over-year GAAP comparison is flattered by a $267 million ERISA litigation charge in Q1 2023, so the 18% Base Business EPS growth is the more representative measure of underlying earnings momentum. Gross margin expanded roughly 310 basis points to 60.0%, and operating margin rose to 20.7% on a GAAP basis (21.4% Base Business). Management raised full-year 2024 guidance: net sales growth to 2% to 5% (from 1% to 4%), now including a mid-single-digit FX headwind, and organic sales growth to 5% to 7% (from 3% to 5%). GAAP EPS is now expected to grow at a double-digit rate, and Base Business EPS at a mid to high-single-digit rate. Management also plans higher advertising investment, which rose 16% in the quarter to $672 million, and signaled strong brand investment for the balance of the year. Cash generation was solid, with operating cash flow of $681 million and free cash flow before dividends of $555 million, though receivables build and a $509 million share repurchase weighed on cash. Growth was led by Latin America (organic sales +25.9%, operating profit +29%) and was supported by North America, Europe and Hill's. Asia Pacific (organic +1.5%) and Africa/Eurasia (organic +16.2%, operating profit -3%) were weaker. Total as-reported volume grew only 1.3%, so the top-line expansion relied heavily on pricing, a point investors may want to monitor for sustainability. Investors should also note that FX remains a material headwind to reported results.

Apr 26, 2024 8-K

Colgate-Palmolive 8-K Report, Executive Changes (Feb 15, 2024)

Colgate-Palmolive Company (CL) announced a significant change to its Board of Directors through an 8-K filing on February 15, 2024. The company has elected Brian Newman, the current Executive Vice President and Chief Financial Officer of United Parcel Service, Inc. (UPS), to join the Board effective March 15, 2024. Mr. Newman brings a wealth of financial and global leadership experience, particularly with 26 years at PepsiCo in various finance and operational roles, which is expected to be highly valuable to Colgate's strategic direction and oversight. This addition of new talent to the Board comes as a result of a planned retirement. Stephen I. Sadove, a current director, will retire at the end of his term and will not seek re-election at the upcoming Annual Meeting of Stockholders on May 10, 2024, in accordance with the company's mandatory director retirement policy. These board transitions are designed to ensure continued strong governance and strategic guidance for Colgate-Palmolive.

Feb 15, 2024 10-K

Colgate-Palmolive Annual Report, Year Ended Dec 31, 2023

Colgate-Palmolive's 2023 results were driven by pricing rather than volume. Worldwide Net sales rose 8.5% to $19,457 million, built on net selling price increases of 10.0% that offset volume declines of 0.5% and a 1.0% foreign exchange headwind. Organic sales grew 8.5%. Gross margin expanded 120 basis points to 58.2%, supported by pricing and funding-the-growth savings, though raw and packaging material inflation of 480 bps was a significant drag. Reported operating profit rose 38% to $3,984 million, but that comparison is flattered by the 2022 Filorga impairment; excluding one-time items, operating profit grew 10% to $4,036 million and the margin reached 20.7%. Diluted EPS was $2.77 on a GAAP basis and $3.23 on a non-GAAP basis, up 9% from $2.97. The quality of earnings warrants attention. Oral, Personal and Home Care organic growth of 8.0% was strong, with toothpaste global share up 1.1 points to 41.1%. Hill's Pet Nutrition organic growth of 10.5% was offset by a 410 bps margin compression to 18.8%, driven by raw material costs and private label mix from recent acquisitions. Several discrete items affected 2023 GAAP results, including a $267 million ERISA pension charge, a $148 million foreign tax matter (partly offset by a $126 million net tax benefit in the reconciliation), and a $25 million Fabuloso recall. Cash generation improved, with operating cash flow of $3,745 million versus $2,556 million, helped by working capital, while capital expenditures were $705 million. Total debt fell to $8,549 million, and Colgate returned about $1.75 billion in dividends and $1.13 billion in buybacks. Looking ahead, management expects continued challenging macro conditions, elevated inflation and higher interest rates, along with category volatility that makes near-term growth difficult to forecast. Key risks include foreign currency exposure, given that about two-thirds of sales come from outside the U.S., heightened competition and retailer concentration (Walmart is roughly 11% of sales), geopolitical disruption from the Ukraine and Israel-Hamas wars, and continued litigation, including talc claims and a Brazilian tax dispute. The 2022 Global Productivity Initiative is expected to conclude by mid-2024 with annualized savings of $90 to $110 million pretax.

Feb 15, 2024 8-K

Colgate-Palmolive 8-K Report, Financial Results (Jan 26, 2024)

Colgate-Palmolive reported fourth quarter and full year 2023 results on January 26, 2024, showing broad-based top-line strength and margin expansion. Q4 2023 net sales and organic sales both rose 7.0% to $4,950 million, with organic volume flat and growth driven almost entirely by pricing (+7.0%). GAAP diluted EPS was $0.87 versus $0.01 in the prior year, but that comparison is distorted by the $721 million goodwill and intangible impairment taken in Q4 2022. On a Base Business (non-GAAP) basis, EPS grew 13% to $0.87 from $0.77, and gross margin expanded roughly 400 basis points to 59.6%. For the full year, net sales and organic sales both grew 8.5% to $19,457 million, the fifth consecutive year of organic growth at or above the company's 3% to 5% target range. GAAP EPS rose 30% to $2.77, while Base Business EPS rose 9% to $3.23. Operating cash flow increased 47% to $3,745 million, and free cash flow before dividends reached $3,040 million, up from $1,860 million. Management also stepped up brand investment, with advertising up 19% to $2,371 million. For 2024, Colgate guided to net sales growth of 1% to 4% including a low-single-digit FX headwind, organic growth within its 3% to 5% long-term range, and double-digit GAAP EPS growth (mid to high-single-digit on a Base Business basis). Investors should weigh the strong pricing-led growth and margin gains against flat organic volume in Q4, a planned step-up in advertising, and the lower guided reported sales growth due to currency. Total debt declined to $8,549 million from $8,766 million, and shareholders' equity remained modest at $609 million.

Jan 26, 2024 8-K

Colgate-Palmolive 8-K Report, Financial Results (Oct 27, 2023)

Colgate-Palmolive reported third-quarter 2023 results that beat on the top and bottom lines and led management to raise full-year 2023 guidance. GAAP net sales rose 10.5% to $4,915 million, and organic sales (excluding FX and acquisitions) grew 9.0%, with growth across five of six divisions and all four categories. GAAP diluted EPS rose 16% to $0.86, and Base Business (non-GAAP) EPS grew at the same rate. Gross margin expanded 130 basis points to 58.5% (58.6% on a Base Business basis), and operating profit grew 9% on a GAAP basis and 12% on a Base Business basis. Net cash from operations for the first nine months was $2,609 million, up 39%. The quality of growth is mixed. Roughly 6 points of the reported sales gain came from pricing (+9.5% company-wide) and about 7.5 points from favorable FX-related translation, while organic volume was slightly negative (-0.5%). Pet food acquisitions added to reported volume, which is a key driver of Hill's growth, and Hill's operating margin fell 410 basis points on higher raw material costs and unfavorable private-label mix. Management still expects significantly higher raw and packaging material costs to be a headwind and continues to fund advertising, which rose more than 20% in the quarter. Management raised its 2023 organic sales growth guidance to 7% to 8% (from 5% to 7%) and its net sales growth guidance to 6% to 8% (from 5% to 8%), and it now expects high-single-digit Base Business EPS growth. The GAAP outlook still calls for double-digit EPS growth. Investors should note that the GAAP results include a $267 million ERISA litigation charge in the nine-month period, which is excluded from Base Business figures, and that shareholders' equity is negative (-$9 million) as of September 30, 2023, largely because of pension and other accumulated items.

Oct 27, 2023 10-Q

Colgate-Palmolive Quarterly Report for Q3 Ended Sep 30, 2023

Colgate-Palmolive Company reported strong top-line growth in the third quarter of 2023, with Net sales increasing by 10.5% to $4.915 billion compared to the prior year period. This growth was driven by a significant 9.5% increase in net selling prices and a modest 0.5% volume increase, alongside a slight positive foreign exchange impact. The company's organic sales, a key non-GAAP metric excluding currency fluctuations and acquisitions, grew by 9.0%. Profitability also saw improvement, with operating profit increasing by 9% to $1.029 billion. Diluted Earnings Per Share (EPS) rose to $0.86, a notable increase from $0.74 in the prior year quarter. Despite ongoing inflationary pressures on raw materials, the company managed to expand its Gross Profit margin to 58.5% due to strategic pricing actions and cost-saving initiatives, though this was partially offset by higher input costs. The Pet Nutrition segment, driven by Hill's Pet Nutrition, showed particularly strong performance with a 21.5% increase in net sales.

Oct 27, 2023 8-K

Colgate-Palmolive 8-K Report, Executive Changes (Sep 15, 2023)

Colgate-Palmolive Company (CL) has filed an 8-K report detailing an amendment to its Executive Severance Plan. The Board of Directors renewed the plan on September 13, 2023, with a primary change requiring participating executives to agree to a one-year non-compete clause following termination of employment. This amendment aims to enhance employee retention and protect the company's competitive interests. The renewed plan will have an initial term of three years, with provisions for automatic one-year extensions unless the Board decides otherwise. This offers a degree of stability for executive compensation and benefits while also introducing a stronger commitment from executives to the company's ongoing success and market position. Investors should note this update as it pertains to executive compensation and potential future executive transitions.

Sep 15, 2023 8-K

Colgate-Palmolive 8-K Report, Executive Changes (Aug 18, 2023)

Colgate-Palmolive Company (CL) has filed an 8-K report on August 18, 2023, to announce a change in its Board of Directors. Michael B. Polk has resigned from his position on the Board, effective August 18, 2023, citing personal reasons for his departure. This filing is primarily informational, detailing the resignation of a director. Investors should note that while any change in board composition can be a point of interest, the stated reason for Mr. Polk's resignation is personal, and no other immediate operational or financial implications are mentioned in this specific filing. The company will continue its business operations under the current management and board structure.

Aug 18, 2023 8-K

Colgate-Palmolive 8-K Report, Financial Results (Jul 28, 2023)

Colgate-Palmolive reported second quarter 2023 results on July 28, 2023, with net sales up 7.5% to $4,822 million and organic sales up 8.0%, driven by pricing of +11.0% while organic volume fell 3.0%. GAAP diluted EPS declined 17% to $0.60, but this was distorted by a $0.15 foreign tax matter charge and $0.02 of 2022 Global Productivity Initiative costs. On a Base Business (non-GAAP) basis, EPS rose 7% to $0.77 and gross margin expanded 80 basis points to 57.8%, though private label sales tied to the pet food acquisitions weighed on margin by about 70 basis points. Operating profit rose 10% on a GAAP basis to $974 million, with Latin America and North America delivering strong margin gains while Europe and Hill's Pet Nutrition faced raw material cost pressure and higher advertising. Management raised its full-year 2023 guidance for net sales growth to 5% to 8% (from prior expectations, including pet food acquisitions and a low-single-digit FX headwind) and organic sales growth to 5% to 7%. Base Business EPS growth is now expected at the high end of mid-single digits, while GAAP double-digit EPS growth is still expected but at a lower level than the Base Business case given the one-time charges. Advertising investment is set to remain elevated in the second half, which management says is needed to support brand health and innovation. Balance sheet and cash flow indicators are mixed. Net cash from operations was $1,457 million for the first half, up sharply from $914 million a year earlier, and free cash flow before dividends reached $1,110 million. However, total debt rose to $8,989 million, and shareholders' equity turned negative at $(64) million, largely due to the first-half ERISA litigation charge and foreign tax matter, which flowed through non-service postretirement costs and tax expense. Investors should weigh the strong top-line momentum and cash generation against elevated input costs, heavy reinvestment, and higher leverage.

Jul 28, 2023 10-Q

Colgate-Palmolive Quarterly Report for Q2 Ended Jun 30, 2023

Colgate-Palmolive Company reported solid top-line growth in the second quarter of 2023, with Net sales increasing by 7.5% to $4.82 billion compared to the prior year. This growth was primarily driven by net selling price increases of 11.0%, though partially offset by a 1.5% decline in volume. Organic sales, excluding foreign exchange and acquisitions, rose by 8.0%. The Pet Nutrition segment, particularly Hill's Pet Nutrition, showed strong performance with a 16.0% increase in Net sales, fueled by both volume and pricing. Despite revenue growth, the company faced a significant increase in its effective income tax rate to 39.8% due to a $148 million discrete tax charge related to reassessed prior-year tax deductions. This, along with other ongoing charges, led to a decrease in net income attributable to Colgate-Palmolive Company to $502 million ($0.60 diluted EPS) from $603 million ($0.72 diluted EPS) in the prior year. Excluding certain discrete items, adjusted net income increased by 6% and adjusted diluted EPS rose by 7%, indicating underlying operational strength despite the tax impact.

Jul 28, 2023 8-K

Colgate-Palmolive 8-K Report, Shareholder Vote Results (May 17, 2023)

This 8-K filing from Colgate-Palmolive Co. (CL) details the results of their Annual Meeting of Stockholders held on May 12, 2023. The primary focus of the report is the outcome of various shareholder votes on critical corporate governance and compensation matters. Key outcomes include the overwhelming re-election of all eleven director nominees to the Board, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and the approval of the company's executive compensation plan on a non-binding advisory basis. Shareholders also voted to continue holding advisory votes on executive compensation annually. Conversely, two stockholder proposals, one concerning an independent Board Chairman and another regarding executives retaining significant stock, did not receive majority support.

May 17, 2023 8-K

Colgate-Palmolive 8-K Report, Financial Results (Apr 28, 2023)

Colgate-Palmolive's first quarter 2023 results (reported April 28, 2023) showed strong top-line momentum but notable margin and earnings pressure. Net sales rose 8.5% to $4.77 billion, and organic sales grew 10.0% with growth in every division and all four categories. Pricing contributed +12.0%, while organic volume was flat and FX reduced sales by 3.5%. The 8.5% reported sales growth was boosted by the acquisitions of pet food businesses, which added about 2.0 points to total company volume and 9.5 points to Hill's. Profitability was weaker. GAAP diluted EPS fell 32% to $0.45, largely due to a $267 million ERISA litigation charge recorded in non-service related postretirement costs. On a Base Business (non-GAAP) basis, EPS declined 1% to $0.73, and gross profit margin fell 160 basis points to 56.9% under pressure from raw and packaging material costs and a 90 basis point drag from lower-margin private label pet food sales. Advertising spending rose 14% to $579 million. Operating cash flow of $735 million and free cash flow before dividends of $572 million were up sharply year over year, supported by working capital and the absence of prior-year restructuring outflows. Management raised its full-year 2023 sales guidance to 3% to 6% net sales growth and 4% to 6% organic sales growth, but lowered its non-GAAP EPS outlook to mid-single-digit growth from prior expectations. It still expects double-digit GAAP EPS growth, which reflects the one-time ERISA charge. Management flagged uncertainty in the global operating environment, particularly in the second half of 2023.

Apr 28, 2023 10-Q

Colgate-Palmolive Quarterly Report for Q1 Ended Mar 31, 2023

Colgate-Palmolive Company reported its first-quarter 2023 financial results, showing a notable increase in net sales, driven primarily by price increases across its product segments. While top-line growth was strong, net income and earnings per share saw a decline compared to the prior year, largely due to significant one-time charges, including a substantial accrual for an ERISA litigation matter and product recall costs. The company's Oral, Personal, and Home Care segment experienced moderate sales growth, while the Pet Nutrition segment, particularly Hill's Pet Nutrition, demonstrated robust growth in both sales and volume. Despite inflationary pressures impacting gross margins, Colgate-Palmolive is strategically managing costs and continuing to invest in advertising and innovation to support its brands and drive long-term growth.

Apr 28, 2023 8-K

Colgate-Palmolive 8-K Report, Corporate Update (Mar 1, 2023)

Colgate-Palmolive Company (CL) has announced the successful issuance and sale of $1.5 billion in aggregate principal amount of senior notes. This offering includes $500 million of 4.800% Senior Notes due 2026, $500 million of 4.600% Senior Notes due 2028, and $500 million of 4.600% Senior Notes due 2033. The issuance was conducted under the company's existing shelf registration statement and was facilitated through an underwriting agreement with several prominent financial institutions. This debt issuance represents a significant capital raising activity for Colgate-Palmolive. Investors should note the specific interest rates and maturity dates for each tranche of notes, which provide a clear picture of the company's cost of borrowing and its long-term debt obligations. The use of proceeds is not detailed in this 8-K filing, but such actions typically support general corporate purposes, potential acquisitions, or refinancing existing debt.

Mar 1, 2023 10-K

Colgate-Palmolive Annual Report, Year Ended Dec 31, 2022

Colgate-Palmolive's FY2022 10-K shows a company with solid underlying momentum but GAAP earnings pressured by a large non-cash impairment. Worldwide Net sales rose 3.0% to $17,967 million, driven by net selling price increases of 9.5%, partially offset by volume declines of 2.0% and a 4.5% foreign exchange headwind. Organic sales grew 7.0%. Hill's Pet Nutrition was the standout, with Net sales up 12.0% and organic growth of 13.0%, while Oral, Personal and Home Care sales grew only 1.0% on a reported basis (5.5% organic) and Europe was weak. Gross margin fell 260 bps to 57.0% as raw and packaging material inflation (810 bps) outran pricing (360 bps) and productivity savings (220 bps). GAAP operating profit fell 13% to $2,893 million, driven by a $721 million pretax goodwill and intangible impairment tied to the Filorga skin health business. Excluding that charge and other items, operating profit declined 5% to $3,681 million, and non-GAAP diluted EPS fell 7% to $2.97 from $3.21. GAAP diluted EPS was $2.13 versus $2.55 in 2021. Operating cash flow dropped to $2,556 million from $3,325 million, largely due to working capital build, and free cash flow after $696 million of capex was roughly $1.9 billion. The company paid $1,691 million in dividends (up to $1.86 per share) and repurchased $1,308 million of stock. Total debt rose to $8,766 million after acquisitions, including Red Collar Pet Foods for $719 million. Management expects a continued difficult cost environment in 2023 with additional pricing that may weigh on volumes, and it flagged ongoing risks from China, travel retail, Ukraine-related disruption, and a multi-year 2022 Global Productivity Initiative with $200-240 million of cumulative charges and $90-110 million of annualized savings.

Feb 16, 2023 8-K

Colgate-Palmolive 8-K Report, Executive Changes (Jan 30, 2023)

Colgate-Palmolive Company (CL) announced a significant addition to its Board of Directors with the election of Steven Cahillane, effective February 1, 2023. Mr. Cahillane, currently the Chairman, President, and CEO of Kellogg Company, brings a wealth of experience in global consumer products and health and nutrition industries, which is highly relevant to Colgate's business. His appointment is expected to enhance the Board's strategic oversight and guidance as the company navigates the evolving consumer landscape.

Jan 30, 2023 8-K

Colgate-Palmolive 8-K Report, Financial Results (Jan 27, 2023)

Colgate-Palmolive reported 4Q 2022 and full-year 2022 results, with net sales up 5.0% in the quarter and 3.0% for the year, and organic sales up 8.5% and 7.0%, respectively. Growth was broad-based across every division and all four categories, and management attributes it to pricing from revenue growth management, productivity savings, and reinvestment in innovation, advertising, and digital. Fourth-quarter volume was down (organic volume -4.0%), so growth was driven primarily by pricing (+12.5%), while FX was a significant drag (-5.0%). Reported profitability was sharply lower because of a non-cash, after-tax goodwill and intangible impairment of $620 million tied to the Filorga skin health business, which pushed GAAP EPS down 94% to $0.01 in the quarter and 16% to $2.13 for the year. On a Base Business (non-GAAP) basis, full-year EPS fell 7% to $2.97, and Q4 EPS fell 3% to $0.77. Gross margin compressed by 250 basis points to 55.6% in the quarter, reflecting significantly higher raw and packaging material costs and a private-label drag from the pet food acquisitions. For 2023, Colgate guided to net sales growth of 2% to 5%, organic sales growth toward the high end of its 3% to 5% long-term range, gross margin expansion, higher advertising, and low-to-mid single-digit Base Business EPS growth. Investors should weigh the strong top-line momentum against margin pressure, Filorga's impairment risk, and the currency headwind that management expects to persist.

Jan 27, 2023 8-K

Colgate-Palmolive 8-K Report, Bylaw Amendment (Jan 12, 2023)

Colgate-Palmolive Company (CL) has filed an 8-K report on January 12, 2023, detailing amendments to its Amended and Restated By-laws, effective January 12, 2023. These changes primarily focus on updating procedures for stockholder proposals, specifically concerning special meetings and director nominations. A key new requirement mandates that stockholders intending to nominate directors must disclose whether they plan to solicit proxies for at least 67% of the company's voting shares. Additionally, the by-laws have been updated to designate a Delaware state or federal court as the exclusive forum for certain legal actions against the company, including derivative suits and claims related to fiduciary duties. These amendments are largely technical and administrative, reflecting updates in line with new SEC universal proxy rules and aiming to streamline corporate governance processes. For investors, the changes mainly impact procedural aspects of engaging with the company for shareholder proposals and director nominations, as well as clarifying legal venue for specific types of lawsuits. The company has also included the full text of the amended by-laws as an exhibit for further review.

Jan 12, 2023 8-K

Colgate-Palmolive 8-K Report, Financial Results (Oct 28, 2022)

Colgate-Palmolive reported third-quarter 2022 results on October 28, 2022. GAAP net sales rose 1.0% to $4,455 million, while organic sales (excluding foreign exchange and M&A) grew 7.0%, with growth in every division and all four categories. Management highlighted a 15th consecutive quarter of organic growth at or above the company's 3% to 5% target range, driven by pricing, which contributed roughly 11.5 points of growth, with volume down 4.5%. Profitability was under pressure: GAAP diluted EPS fell 1% to $0.74, and Base Business (non-GAAP) EPS fell 9% to $0.74 from $0.81, as gross margin contracted about 220 basis points to 57.2% on sharply higher raw material, packaging and logistics costs. Foreign exchange was a meaningful drag, reducing sales by about 6 points and EPS by $0.05. Management raised its full-year organic sales growth guidance to 6% to 7% from 5% to 7%, and now expects reported net sales growth in the middle of the 1% to 4% range, reflecting roughly a 5% FX headwind. Non-GAAP EPS is now guided to decline 7% to 8%, reflecting the incremental FX impact since the prior guidance. Gross margin is still expected to decline, and advertising is now expected to be roughly flat. For investors, the quarter shows strong pricing power and top-line momentum offset by margin compression and currency headwinds. Cash generation remained solid, with nine-month operating cash flow of $1,883 million and free cash flow before dividends of $1,408 million, though down from the prior year. Debt rose to $8,248 million from $7,245 million at year-end 2021, partly reflecting financing for the Red Collar acquisition, which contributed a modest benefit to sales.

Oct 28, 2022